Assessing Sumitomo Pharma (TSE:4506) Valuation After Recent Share Price Volatility

Setting the scene for Sumitomo Pharma’s recent share performance

Sumitomo Pharma (TSE:4506) has seen its share price move in different directions across timeframes, with a gain of 1.6% over the past day and a decline of 25.2% over the past 3 months.

See our latest analysis for Sumitomo Pharma.

At a share price of ¥1,437.0, the stock has recently fallen over shorter periods, with the 30 day share price return down 16.9% and the year to date share price return down 41.6%. However, the 1 year total shareholder return is 78.7%, suggesting that earlier optimism is now cooling.

If recent volatility has you rethinking sector exposure, it can help to widen the lens and look at other opportunities using a focused screener such as 7 healthcare AI stocks

With Sumitomo Pharma trading at ¥1,437 and indications of a discount to some valuation estimates, investors are left with a key question: is this genuine value, or is the current price already reflecting future growth?

Most Popular Narrative: 33.4% Undervalued

Sumitomo Pharma’s most followed narrative points to a fair value of ¥2,158, compared with the last close at ¥1,437, putting the current discount in sharp focus.

Heavy reliance on ORGOVYX and GEMTESA in North America, alongside loss of exclusivity for products like APTIOM, Equa and TRERIEF, increases exposure to future generic entry and reimbursement pressure, which could weigh on revenue durability and long term earnings quality.

Read the complete narrative.

Want to see what is driving that gap between price and narrative value? The projections juggle moderating margins, steady top line growth and a future earnings multiple that sits below the wider pharma sector. The full narrative joins those moving parts into one valuation story.

Result: Fair Value of ¥2,158 (UNDERVALUED)

Have a read of the narrative in full and understand what’s behind the forecasts.

However, the story could change if North America keeps delivering strong contributions for ORGOVYX and GEMTESA, or if the oncology and iPS cell therapy pipeline progresses faster than expected.

Find out about the key risks to this Sumitomo Pharma narrative.

Next Steps

With mixed signals on value, risk and future potential, this is a moment to look at the data yourself and decide where you stand. To help you weigh both sides in one place, check out the 4 key rewards and 4 important warning signs

Looking for more investment ideas?

If you stop at a single stock, you risk missing opportunities that better fit your goals, so put screeners to work and compare ideas side by side.

This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com